19:05 , Aug 10, 2018 |  BC Week In Review  |  Company News

Zepatier lands co-exclusive status on Express Scripts 2019 formulary

Express Scripts Holding Co. (NASDAQ:ESRX) announced its 2019 National Preferred Formulary Exclusions , noting that the exclusions were driven not only by the size of the rebate as in years past, but also by lower...
16:28 , Aug 10, 2018 |  BC Week In Review  |  Company News

Ironwood ends gout drug deal with AZ

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) terminated its deal with AstraZeneca plc (LSE:AZN; NYSE:AZN) for rights to the pharma's gout drugs Zurampic lesinurad and Duzallo lesinurad/allopurinol. Ironwood said franchise test markets of the drugs did not meet...
20:46 , Aug 7, 2018 |  BC Extra  |  Company News

Zepatier lands co-exclusive status on Express Scripts 2019 formulary

Express Scripts Holding Co. (NASDAQ:ESRX) announced its 2019 National Preferred Formulary Exclusions , noting that the exclusions were driven not only by the size of the rebate as in years past, but also by lower...
21:22 , Aug 6, 2018 |  BC Extra  |  Company News

Ironwood ends gout drug deal with AZ

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) terminated its deal with AstraZeneca plc (LSE:AZN; NYSE:AZN) for rights to the pharma's gout drugs Zurampic lesinurad and Duzallo lesinurad/allopurinol. Ironwood said franchise test markets of the drugs did not meet...
20:07 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

EMA's CHMP recommends CAR Ts, rare disease therapies

EMA's CHMP recommended for approval Kymriah tisagenlecleucel and Yescarta axicabtagene ciloleucel, the first two CAR T therapies backed by the committee. CHMP also recommended a handful of other Orphan drug candidates, including Cablivi caplicizumab, a...
20:20 , Jun 29, 2018 |  BC Extra  |  Company News

CHMP backs CAR Ts, Orphan candidates

EMA's CHMP recommended for approval Kymriah tisagenlecleucel and Yescarta axicabtagene ciloleucel, the first two CAR T therapies backed by the committee. CHMP also recommended a handful of other Orphan drug candidates, including Cablivi caplicizumab, a...
00:12 , May 5, 2018 |  BioCentury  |  Finance

Splitting Ironwood

Ironwood Pharmaceuticals Inc. has accomplished what many biotechs aspire to but few achieve. It has built a high-growth GI business on the cusp of profitability, and discovered and developed a well-stocked pipeline of clinical candidates...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
23:52 , Oct 6, 2017 |  BioCentury  |  Finance

Bargain shopping

With all companies valued over $1 billion increasing a median of at least 16.8% in 1H17, investors went bargain shopping in the $500-$999 million tier in 3Q17. The group outperformed all other market cap bands,...
23:09 , Aug 28, 2017 |  BC Week In Review  |  Clinical News

FDA approves Ironwood's Duzallo for gout

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) said FDA approved Duzallo lesinurad/allopurinol to treat hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with allopurinol alone. The company expects to launch the...